Provided by Tiger Trade Technology Pte. Ltd.

Mineralys Therapeutics, Inc.

25.57
-0.1000-0.39%
Post-market: 25.570.00000.00%19:30 EDT
Volume:728.42K
Turnover:18.45M
Market Cap:2.25B
PE:-5.84
High:26.33
Open:25.47
Low:24.98
Close:25.67
52wk High:47.65
52wk Low:22.00
Shares:88.16M
Float Shares:66.03M
Volume Ratio:0.92
T/O Rate:1.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3763
EPS(LYR):-2.2900
ROE:-80.88%
ROA:-46.18%
PB:4.09
PE(LYR):-11.17

Loading ...

Mineralys Therapeutics Joins Wells Fargo Annual Healthcare Conference Fireside Chat

Reuters
·
Aug 26

Mineralys Chief Commercial Officer Eric Warren Disposes of 7,437 Common Shares Worth $193,226

Reuters
·
Aug 26

Why Mineralys Therapeutics (MLYS) Is Getting Fresh Attention

Simply Wall St.
·
Aug 23

Does New CMO Hire and Heavier Leverage Reshape the Bull Case For Mineralys Therapeutics (MLYS)?

Simply Wall St.
·
Aug 19

Mineralys Grants New CMO Inducement Awards for 135,000 Stock Options, 102,400 RSUs

Reuters
·
Aug 14

Mineralys Therapeutics Reports Inducement Award Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 14

Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)

TIPRANKS
·
Aug 13

Mineralys Therapeutics Confronts Heightened Refinancing and Liquidity Risks as 2031 Debt Maturity Looms

TIPRANKS
·
Aug 13

Mineralys Therapeutics CMO David Malcom Rodman Disposes of USD 58,785.3 in Common Shares

Reuters
·
Aug 13

Mineralys Therapeutics Names James J. Ferguson III as Chief Medical Officer in Form 3 Beneficial Ownership Filing

Reuters
·
Aug 13

Goldman Sachs Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

TIPRANKS
·
Aug 12

Mineralys Therapeutics Publishes Corporate Presentation on Lorundrostat for Uncontrolled, Resistant Hypertension and Cardiorenal Diseases

Reuters
·
Aug 12

Mineralys Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Mineralys Therapeutics Q2 Loss Widens

MT Newswires Live
·
Aug 12

Earnings Flash (MLYS) Mineralys Therapeutics Posts Q2 Loss $2.85, vs. FactSet Est of $0.55 Loss

MT Newswires Live
·
Aug 12

Mineralys Therapeutics Catat Rugi Bersih Kuartal II FY26 Melebar Jadi USD 241,07 Juta; Belanja R&D Melonjak Jadi USD 221,38 Juta

Reuters
·
Aug 12

Press Release: Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 12

Mineralys Therapeutics to Report Q2 Results, Host Conference Call

Reuters
·
Aug 04

Mineralys Therapeutics Grants Inducement Equity Awards to New Hires Under 2025 Plan

Reuters
·
Jul 28

Mineralys Therapeutics Reports Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 28